These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 33807964

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.
    Sakamoto S, Takahashi H, Inoue Y, Arai Y, Inoda S, Kakinuma N, Fujino Y, Tanabe T, Kawashima H, Yanagi Y.
    Clin Ophthalmol; 2018; 12():1137-1147. PubMed ID: 29970955
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.
    Park JY, Park YJ, Park SJ, Park KH, Yeo JH, Kim JG, Yoon YH, Lee JY, Woo SJ.
    Acta Ophthalmol; 2022 Dec; 100(8):e1579-e1588. PubMed ID: 35363434
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC, Lee DK, Kim SH, You YS, Kwon OW.
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Hamid MA, Abdelfattah NS, Salamzadeh J, Abdelaziz STA, Sabry AM, Mourad KM, Shehab AA, Kuppermann BD.
    Int J Retina Vitreous; 2021 Apr 01; 7(1):26. PubMed ID: 33795022
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration: Efficacy and Macular Atrophy Development.
    Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H.
    Ophthalmol Retina; 2018 May 01; 2(5):462-468. PubMed ID: 31047326
    [Abstract] [Full Text] [Related]

  • 17. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
    Huang CH, Lai TT, Yang CH, Hsieh YT.
    Ophthalmol Ther; 2024 Jan 01; 13(1):385-396. PubMed ID: 37995014
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK, Tsai FF, Gaber R, Alam M, Meshi A, Freeman WR.
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr 01; 255(4):709-717. PubMed ID: 27878592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.